Recent Quotes (30 days)

You have no recent quotes
chg | %

Takeda Pharmaceutical Co Ltd news

   Watch this stock
Showing stories 1 - 10 of about 124   

Articles published

4502 6,291.00 +43.00 (0.69%)
price chart
Takeda Pharmaceutical Co Ltd (ADR) Plans To Offer $2.2 Billion To Settle Actos ...
Takeda Pharmaceutical Co Ltd (ADR) (OTCMKTS:TKPYY) has, as per anonymous sources, expressed its willingness to put down over $2.2 billion in an attempt to settle claims that the company deliberately withheld information about the risk of cancer from ...
Drugmaker Takeda may settle Actos suits for $2.2 billion  The Japan Times
Takeda Said to Offer $2.2 Billion to Settle Actos Drug Cases  Bloomberg
BioMotiv and Takeda Pharmaceutical Company Enter into Strategic Partnership
CLEVELAND & OSAKA, Japan, Sep 25, 2014 (BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (�Takeda�) and BioMotiv, LLC, the therapeutic accelerator company associated with The Harrington Project for Discovery & Development, jointly ...
Related articles »  
TWi signs Settlement Agreement with Takeda on patent litigation related to ...
TWi Pharmaceuticals, Inc. ("TWi") today announced that it has entered into a Settlement Agreement with Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals U.S.A., Inc., Takeda Pharmaceuticals America, Inc. (individually and collectively, ...
TWi settles Dexilant patent litigation with Takeda  pharmabiz.com
TWi, Takeda Settle Generic Dexilant Patent Suit  Law360 (subscription)
Takeda Said to Agree to Pay $2.3 Billion to Settle Actos Cases
Takeda Pharmaceutical Co. executives have agreed to pay more than $2.3 billion to resolve lawsuits accusing the company of hiding its Actos diabetes medicine's cancer risks, three people familiar with the accord said. Takeda directors still must vote ...
CiRA & Takeda Undertake US$267 Million iPS Collaboration
AsianScientist (Apr. 22, 2015) - Center for iPS Cell Research Application (CiRA) of Kyoto University and Takeda Pharmaceutical Company Limited (Takeda) will work together to develop clinical applications of induced pluripotent (iPS) stem cells.
Market Update (NASDAQ:AMGN): Amgen's cancer immunotherapy fails to ...
Amgen Inc (NASDAQ:AMGN) [Reuters] - U.S. Food and Drug Administration staff reviewers said an accelerated review of drugmaker Amgen Inc's skin cancer immunotherapy cannot be considered at this time, citing concerns over the design and results of a ...
Infinity Pharma buys out royalty obligations from Takeda for $52.5M
Infinity Pharmaceuticals (INFI +0.1%) exercises its option to buy out all future royalty obligations due to Takeda Pharmaceutical Company Limited (OTCPK:TKPHF) (OTCPK:TKPYY) on sales of duvelisib (IPI-145) in oncology indications for an exercise fee of ...
Infinity Exercises Option to Buy Out All Future Royalty Obligations to ...  PharmiWeb.com (press release)
Merck diabetes drug Januvia meets heart safety target
Earlier this month, a panel of expert advisers to the U.S. Food and Drug Administration voted that two similar diabetes drugs, AstraZeneca Plc (NYSE: AZN - news) 's Onglyza and Nesina from Takeda Pharmaceutical Co Ltd, had acceptable cardiovascular ...
FDA Advisory Committee Reviews Takeda's Alogliptin EXAMINE Cardiovascular ...
DEERFIELD, Ill. and OSAKA, Japan, April 14, 2015 /PRNewswire/ -- Takeda Pharmaceuticals U.S.A. Inc. and Takeda Pharmaceutical Company Limited, ("Takeda") today announced that members of the Endocrinologic and Metabolic Drugs Advisory ...
New Takeda type 2 diabetes treatments NESINA� (alogliptin) and KAZANO ...  Canada NewsWire (press release)
DA Advisory Committee Reviews Takeda's Alogliptin EXAMINE Cardiovascular ...  The FINANCIAL
CiRA, Takeda collaborate to develop clinical applications of iPS cells
Center for iPS Cell Research Application (CiRA) of Kyoto University and Takeda Pharmaceutical Company Limited (Takeda) announced today that they will work together to develop clinical applications of induced pluripotent stem cells in areas such as ...
CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research  SYS-CON Media (press release)